Filing Flows › Iradimed (IRMD) › R&D spending
Iradimed (IRMD) R&D spending by quarter
Iradimed's R&D spending was $875K in Q3 2026 (third quarter 2026), +33% from Q2 2026. Over the last 7 quarters it ranged from $624K (Q1 2025) to $956K (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $875K | +33% | +30% |
| Q2 2026 | $657K | -31% | -25% |
| Q1 2026 | $956K | +20% | +53% |
| Q4 2025 | $799K | +19% | — |
| Q3 2025 | $674K | -23% | — |
| Q2 2025 | $877K | +41% | — |
| Q1 2025 | $624K | — | — |
Q3 2026 at a glance
Iradimed, Q3 2026: revenue $24.2M (+14% year over year), operating margin 33.6%, net earnings $6.5M, operating cash flow $7.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Iradimed's R&D spending?
Iradimed's R&D spending was $875K in Q3 2026 (third quarter 2026), +33% from Q2 2026.
How has Iradimed's R&D spending changed?
Over the last 7 quarters it ranged from $624K (Q1 2025) to $956K (Q1 2026).